Vertex’s new drug Journavx (suzetrigine) has been hailed as a scientific breakthrough because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

Whereas opioids block pain receptors in the brain, the FDA says Journavx works by "targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system" before those pain ...

The FDA approved Journavx on Thursday following a pair of clinical trials on 874 participants with moderate to severe acute pain following abdominoplasty — commonly known as a "tummy tuck ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain ... drug pipeline that involves winning FDA approval for multiple drugs across several ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.